Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Manabu Kawai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3506-9895; OpenAlex author ID A5051950705. Sources: OpenAlex.

Their work

Papers
52 (first author 10, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
143
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 3 papers · 2016: 5 papers · 2017: 5 papers · 2018: 3 papers · 2019: 1 paper · 2020: 5 papers · 2021: 5 papers · 2022: 5 papers · 2023: 5 papers · 2024: 4 papers · 2025: 2 papers · 2026: 5 papers

Papers 50 of 52

  1. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Co-author DOI 10.1016/j.gie.2026.05.032↗
  2. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  3. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Co-author DOI 10.1097/mpa.0000000000002694↗
  4. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Co-author DOI 10.1097/sla.0000000000007012↗
  5. In vitro functional analysis of lysyl oxidase family members in highly metastatic pancreatic cancer cells derived from a syngeneic orthotopic model. Co-author DOI 10.1186/s12885-026-16173-1↗
  6. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  7. Octogenarians with lower BMI have comparatively poor survival in potentially resectable pancreatic cancer: outcomes over 5-year follow-up. Last author DOI 10.1016/j.suronc.2025.102248↗
  8. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… First author DOI 10.1002/jhbp.12066↗
  9. Scoring system to predict positive peritoneal cytology in patients with resectable and borderline resectable pancreatic cancer. Last author DOI 10.1002/jhbp.1436↗
  10. Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer. Last author DOI 10.1007/s00432-023-05594-1↗
  11. Insight from Lymphocyte-Albumin Scores into Treatment Continuity of Nanoliposomal Irinotecan With 5-Fluorouracil and L-leucovorin in Metastatic Pancreatic Canc… Co-author DOI 10.21873/invivo.13768↗
  12. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Co-author DOI 10.1002/ags3.12712↗
  13. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  14. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  15. Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2023.06.012↗
  16. Utility of contrast-enhanced harmonic endoscopic ultrasonography for prediction of pathological response after neoadjuvant chemotherapy in patients with pancre… Co-author DOI 10.1016/j.pan.2023.10.016↗
  17. Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gem… Co-author DOI 10.1016/j.pan.2021.12.013↗
  18. Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cance… Co-author DOI 10.1016/j.pan.2022.04.005↗
  19. Supervised Exercise Therapy and Adjuvant Chemotherapy for Pancreatic Cancer: A Prospective, Single-Arm, Phase II Open-Label, Nonrandomized, Historically Contro… Co-author DOI 10.1097/xcs.0000000000000408↗
  20. Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by… First author DOI 10.1245/s10434-021-10985-0↗
  21. Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers14030551↗
  22. Advances in immunotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.944↗
  23. Computed tomography findings for predicting the future occurrence of pancreatic cancer: value of pancreatic volumetry. Co-author DOI 10.1007/s10147-021-01915-x↗
  24. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreat… First author DOI 10.1016/j.ejso.2021.06.005↗
  25. Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline rese… Co-author DOI 10.1111/den.13926↗
  26. Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: A prospective study. Co-author DOI 10.1111/jgh.15661↗
  27. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). First author DOI 10.1007/s00423-020-01857-4↗
  28. Fully covered self-expandable metal stent with an anti-migration system vs plastic stent for distal biliary obstruction caused by borderline resectable pancrea… Co-author DOI 10.1097/md.0000000000018718↗
  29. Preoperative In-Hospital Rehabilitation Improves Physical Function in Patients with Pancreatic Cancer Scheduled for Surgery. Co-author DOI 10.1620/tjem.251.279↗
  30. Preoperative Scoring System to Predict Prognosis in Patients Who Undergo Neoadjuvant Therapy for Pancreatic Cancer. First author DOI 10.21873/anticanres.14399↗
  31. Utility of Contrast-Enhanced Harmonic Endoscopic Ultrasonography for Early Diagnosis of Small Pancreatic Cancer. Co-author DOI 10.3390/diagnostics10010023↗
  32. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2018.12.015↗
  33. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgica… Co-author DOI 10.1016/j.pan.2017.11.005↗
  34. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomize… First author DOI 10.1186/s13063-018-3002-z↗
  35. [Evidence of Neoadjuvant Treatment for Pancreatic Cancer]. Co-author PMID 30382034↗
  36. Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. First author DOI 10.1002/ags3.12013↗
  37. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Co-author DOI 10.1002/ijc.30510↗
  38. Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3 Pancreatic Adenocarcinoma: Proposal for Recl… Co-author DOI 10.1007/s00268-017-4077-5↗
  39. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multi… Co-author DOI 10.1159/000478660↗
  40. Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.11389↗
  41. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. Co-author DOI 10.1002/jhbp.320↗
  42. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. First author DOI 10.1007/s00280-016-3121-8↗
  43. Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: A multicenter observational study. Co-author DOI 10.1016/j.surg.2016.02.032↗
  44. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Grou… Co-author DOI 10.1097/mpa.0000000000000579↗
  45. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement. First author DOI 10.1097/mpa.0000000000000634↗
  46. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. Co-author DOI 10.1007/s00535-014-1005-4↗
  47. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. Co-author DOI 10.1007/s11605-014-2637-7↗
  48. Impact of Preoperative Biliary Drainage on Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma: A Multicenter Observational Study. Co-author DOI 10.1245/s10434-015-4618-9↗
  49. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1002/jhbp.109↗
  50. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-013-2323-6↗

Closest collaborators

The 25 strongest of 143 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroki Yamaue · 37 shared papers, 2011–2024 · strength 3.30
  2. Seiko Hirono · 28 shared papers, 2012–2026 · strength 2.58
  3. Yuji Kitahata · 20 shared papers, 2012–2025 · strength 2.30
  4. Ken‐ichi Okada · 24 shared papers, 2012–2024 · strength 2.22
  5. Motoki Miyazawa · 20 shared papers, 2012–2024 · strength 1.95
  6. Michiaki Unno · 15 shared papers, 2015–2026 · strength 1.69
  7. Sohei Satoi · 17 shared papers, 2014–2026 · strength 1.62
  8. Reiko Ashida · 8 shared papers, 2021–2024 · strength 1.15
  9. Yuki Kawaji · 9 shared papers, 2020–2023 · strength 1.09
  10. Keiichi Hatamaru · 9 shared papers, 2020–2023 · strength 1.09
  11. Masahiro Itonaga · 9 shared papers, 2020–2023 · strength 1.09
  12. Takashi Tamura · 9 shared papers, 2020–2023 · strength 1.09
  13. Yasunobu Yamashita · 9 shared papers, 2020–2023 · strength 1.09
  14. Masayuki Kitano · 9 shared papers, 2020–2023 · strength 1.09
  15. Ippei Matsumoto · 13 shared papers, 2015–2025 · strength 0.99
  16. Atsushi Shimizu · 10 shared papers, 2012–2024 · strength 0.96
  17. Hideki Motobayashi · 5 shared papers, 2022–2025 · strength 0.93
  18. Tomohiro Yoshimura · 4 shared papers, 2023–2025 · strength 0.78
  19. Tomoya Emori · 6 shared papers, 2021–2022 · strength 0.74
  20. Masamichi Mizuma · 5 shared papers, 2015–2026 · strength 0.74
  21. Masayuki Sho · 11 shared papers, 2015–2026 · strength 0.73
  22. Atsushi Miyamoto · 4 shared papers, 2022–2025 · strength 0.72
  23. Yuichi Nagakawa · 4 shared papers, 2018–2026 · strength 0.61
  24. Hirofumi Akita · 3 shared papers, 2025–2026 · strength 0.61
  25. Kenichiro Uemura · 9 shared papers, 2015–2026 · strength 0.61

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.